Bendamustine in Metastatic Breast Cancer: An Old Drug in New Design.

Abstract

The goal of treatment for patients with advanced breast cancer is to prolong survival, control symptoms, and reduce disease-related complications. Despite the introduction of many cytotoxic agents during the past decade, only modest improvement in survival in metastatic breast cancer has been achieved. In order to improve this situation, new cytotoxic drugs as well as molecule-targeted agents are now under investigation. Bendamustine is a bifunctional alkylating agent with cytotoxic activity against several types of solid tumors. In the search for new anthracycline-free combinations, taxanes and alkylating agents might be worth investigating, in order to reduce cardiac toxicity. In this article, we reviewed the latest information regarding antitumor activity, toxicity, pharmacokinetics, and clinical application of bendamustine as a cytotoxic agent in metastatic breast cancer.

• Authors: Cristina Pirvulescu, Gunter von Minckwitz, Sibylle Loibl
• Journal: Breast care (Basel, Switzerland) (Breast Care (Basel)) Vol. 3 Issue 5 Pg. 333-339 ( 2008) ISSN: 1661-3791 [Print] Switzerland
• PMID: 20824028 (Publication Type: Journal Article)